SBX Stock Overview
Engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SynBiotic SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.58 |
| 52 Week High | €16.35 |
| 52 Week Low | €2.89 |
| Beta | 4.49 |
| 11 Month Change | 0.36% |
| 3 Month Change | -11.15% |
| 1 Year Change | 89.15% |
| 33 Year Change | -73.68% |
| 5 Year Change | 365.00% |
| Change since IPO | 431.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -7.0% | -0.4% |
| 1Y | 89.2% | -21.6% | 7.1% |
Return vs Industry: SBX exceeded the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: SBX exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| SBX volatility | |
|---|---|
| SBX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine SBX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 55 | Lars Muller | www.synbiotic.com |
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE.
SynBiotic SE Fundamentals Summary
| SBX fundamental statistics | |
|---|---|
| Market cap | €29.93m |
| Earnings (TTM) | -€10.63m |
| Revenue (TTM) | €3.86m |
7.2x
P/S Ratio-2.6x
P/E RatioIs SBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBX income statement (TTM) | |
|---|---|
| Revenue | €3.86m |
| Cost of Revenue | €2.35m |
| Gross Profit | €1.51m |
| Other Expenses | €12.14m |
| Earnings | -€10.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 39.01% |
| Net Profit Margin | -275.31% |
| Debt/Equity Ratio | 23.7% |
How did SBX perform over the long term?
See historical performance and comparison